345635-33-8

Upstream product

• 1254175-56-8 C₁₆H₁₉ClO₄S 
• 1265819-85-9 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-acrylic acid dicyclohexylamine salt 
• 872-53-7 cyclopentanealdehyde 
• 1265819-83-7 (3-Chloro-4-methanesulfonyl-phenyl)acetic acid 
• 87776-75-8 (3-chloro-4-methylsulfanyl-phenyl)-acetic acid 

Downstream Products

• 1265819-87-1 (E)-2-(3-Chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-acrylic acid Sodium Salt 
• 1265819-90-6 (R)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionic acid, dicyclohexylamine salt 
• 1266162-63-3 (R)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionic acid acid sodium salt 
• 1265819-85-9 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-acrylic acid dicyclohexylamine salt 
• 300356-14-3 (R)-2-(3-chloro-4-(methylsulfonyl)phenyl)-3-cyclopentylpropanoic acid 
• 1265819-92-8 (S)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionic acid 
• 928218-39-7 (2E)-2-[3-chloro-4-(methylsulfonyl)phenyl]-3-cyclopentyl-N-[4-(2,2-dimethyl-1,3-dioxolan-4-yl)-1,3-thiazol-2-yl]acrylamide 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF (R)-2-PHENYL PROPIONIC ACID DERIVATIVES

The present invention relates to a process for the preparation of (R)-2-phenyl propionic acid derivatives of the formula wherein R1 is C1-6-alkyl and R2 is hydrogen or halogen, or of a salt thereof.

PROCESS FOR THE PREPARATION OF (R)-2-PHENYL PROPIONIC ACID DERIVATIVES

The present invention relates to a process for the preparation of (R)-2-phenyl propionic acid derivatives of the formula (I) wherein R1 is C1-6-alkyl and R2 is hydrogen or halogen, or of a salt thereof. (R)-2-phenyl propio

2,3-Disubstituted acrylamides as potent glucokinase activators

The phenylacetamide 1 represents the archtypical glucokinase activator (GKA) in which only the R-isomer is active. In order to probe whether the chiral center could be replaced, we prepared a series of olefins 2 and show in the present work that these com

Trans olefinic glucokinase activators

2,3-Di-substituted trans olefinic N-heteroaromatic or urido propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.